Measurement of beta-amyloid peptides in specific cells using a photo thin-film transistor
© Kim et al; licensee Springer. 2012
Received: 26 July 2011
Accepted: 6 January 2012
Published: 6 January 2012
The existence of beta-amyloid [Aβ] peptides in the brain has been regarded as the most archetypal biomarker of Alzheimer's disease [AD]. Recently, an early clinical diagnosis has been considered a great importance in identifying people who are at high risk of AD. However, no microscale electronic sensing devices for the detection of Aβ peptides have been developed yet. In this study, we propose an effective method to evaluate a small quantity of Aβ peptides labeled with fluorescein isothiocyanate [FITC] using a photosensitive field-effect transistor [p-FET] with an on-chip single-layer optical filter. To accurately evaluate the quantity of Aβ peptides within the cells cultured on the p-FET device, we measured the photocurrents which resulted from the FITC-conjugated Aβ peptides expressed from the cells and measured the number of photons of the fluorochrome in the cells using a photomultiplier tube. Thus, we evaluated the correlation between the generated photocurrents and the number of emitted photons. We also evaluated the correlation between the number of emitted photons and the amount of FITC by measuring the FITC volume using AFM. Finally, we estimated the quantity of Aβ peptides of the cells placed on the p-FET sensing area on the basis of the binding ratio between FITC molecules and Aβ peptides.
KeywordsAlzheimer's disease beta-amyloid photosensitive field-effect transistor arsenic trisulfide optical filter
Since the discovery of Alzheimer's disease [AD] in 1906, numerous AD researches have grown intensively from many angles during the past several decades [1–4]. Recently, the importance of early clinical diagnosis has been recognized to diagnose people at high risk of AD. According to the established hypotheses on AD during the past decade, the extracellular deposits of beta-amyloid [Aβ] peptides forming plaques and the intracellular neurofibrillary tangles have been regarded as the major histopathological hallmarks of AD [5–10]. Biologically, more evolved studies examined that Aβ peptides which are incorporated into planar lipid bilayers of neurons induce multimeric ion channels inducing excessive calcium influx into neurons and subsequent neuritic degeneration and death . Another hypothesis suggested that soluble Aβ oligomers are the origin of neurotoxicity before Aβ aggregation process proceeds further and forms plaques .
As an Aβ detection tool, highly sophisticated neuroimaging techniques have been developed such as single photon emission computed tomography  and positron-emission tomography . However, the neuroimaging systems have rather limitations in spatial resolution for the identification of nanoscale Aβ with a molecular-level precision because their detection depends on the computed images of Aβ plaque clumps. Recently, with rapid development of microtechnology, the incorporation of microfabricated devices with biochemical analysis techniques has been dramatically increased. Antibody-conjugated microbead arrays on a substrate were used for a multiplexed detection of several types of proteins in a microelectrophoretic device, which was, however, also on the basis of a fluorescence imaging technique . Surface-enhanced Raman scattering spectroscopy was utilized to detect biomolecules in a label-free way when electrokinetically preconcentrated to amplify the low concentrations, which is also difficult for accurate quantification.
As a result of the recent AD researches, the in vivo physiological quantity of Aβ peptides has been known to be a few nanomoles in concentration. Therefore, the development of biosensors enabling the accurate quantification of a small amount of Aβ peptides ranging from a few femtomoles to nanomoles is required. These challenging biosensors with the capability of Aβ peptide quantification at a low concentration have not been developed yet for early AD diagnosis. Thus, this study suggests a new approach capable of evaluating a small quantity of Aβ peptide using a simple, thin-film field-effect transistor and shows the results of the photocurrents resulted from a fluorescence signal.
Photosensitive field-effect transistor
where C represents an arbitrary constant. Since the absorbance, Aλ, is proportionate to the volume (or mass, or thickness) and the concentration of the absorbing species, Equation 5 meaningfully indicates that high electrical current may be generated by the p-FET device for a large amount of the Aβ-conjugated fluorochrome and vice versa. Eventually, since the quantity of Aβ peptides is directly proportionate to that of the tagged fluorochrome, the photocurrents generated by p-FET are a function of the amount of Aβ peptides specifically conjugated with fluorochrome.
Even though the exact relationship would not be available in a form of an equation in this study, the photocurrent generated by the p-FET device would be expressed as a linear function of the amount of the Aβ-conjugated fluorochrome and potentially provide the quantified Aβ concentration.
Results and discussion
Fluorochrome-conjugated Aβ expressed on a cell line
We prepared HeLa cells for the expression of Aβ peptides. The HeLa cells (density 104/μl) were brought to the p-FET surface and cultured overnight in the incubator for stabilization as shown in Figure 2b. Thereafter, the HeLa cells were fixed with 4% paraformaldehyde for 1 h at room temperature, and then, the blocking with 4% bovine serum albumin was carried out for 1 h to protect nonspecific antibody bindings in the next step. Then, the overnight incubation with a primary antibody (Abcam, Cambridge, MA, USA) was performed for the specific binding to Aβ peptides on the HeLa cells.
The subsequent treatment with a secondary antibody (Invitrogen, Carlsbad, CA, USA) tagged with FITC was performed for 1 h (Figure 2c). The synthetic ratio of Aβ to FITC is defined to be 1:4 by the manufacturer (USBiological, Swampscott, MA, USA). After the fluorescence treatment with FITC, the nuclei of the HeLa cells were stained using 4',6-diamidino-2-phenylindole [DAPI] (Figure 2d), and the p-FET sensor was imaged using a fluorescent microscope and was irradiated by a 405-nm blue laser as an excitation source for FITC to measure the photocurrent. The reason that we used the 405-nm blue laser was attributed to the intention of forming a thin, single-layer filter on the p-FET surface, not using multilayer, commercial optical filters. We developed a thermally evaporated thin arsenic trisulfide (As2S3) filter which almost blocks the lights below 450 nm and transmits longer than approximately 500 nm. Figure 2e, f shows the typical morphologies of HeLa cells cultured on a flat PDMS surface.
Quantification of Aβ peptides via detection of FITC
Figure 3c shows the FITC-stained HeLa cells with better cellular shapes on a flat PDMS surface. To evaluate the correlation between the generated photocurrent and the number of emitted photons from a single cell, we measured the number of photons of the single cell in the yellow dotted circle using a photomultiplier tube [PMT]. As a result of the PMT measurement, a single fluorescent cell emitted approximately 1.3 × 106 photons in 1 s, which corresponds to 17 nA of photocurrent when compared to the p-FET measurement.
To accurately evaluate the quantity of Aβ peptides within a single cell as the ultimate purpose of this study, the information on how many FITC molecules exist within a single cell is imperatively required. Therefore, as shown in Equation 4, the quantum yield for FITC molecules experimentally measured 0.12, which was excited at 405 nm and emitted at 510 nm. According to both the measured quantum yield for our system and the PMT result for the photon number within a single cell (approximately 1.3 × 106 photons), the concentration of FITC molecules existing within a single cell was roughly evaluated to be approximately 10 fM. After all, the photocurrent of 220 nA measured by p-FET for 13 HeLa cells represents approximately 130 fM of FITC molecules, and the concentration of Aβ peptides is evaluated to be 40 to 50 fM on the basis of the manufacturer synthesis ratio (4:1) between FITC and Aβ. Figure 3d represents the calibration data of the photon counting using PMT measurement, showing a linear function of the FITC volume.
We proposed an effective method to measure the quantity of Aβ peptides labeled with FITC using a p-FET with an on-chip single-layer optical filter. To accurately evaluate the quantity of Aβ peptides within the cells cultured on the p-FET device, we measured the photocurrents which resulted from the FITC-conjugated Aβ peptides expressed from the cells and measured the number of photons of the fluorochrome in the cells using a PMT. Thus, we evaluated the correlation between the generated photocurrents and the number of emitted photons. We also evaluated the correlation between the number of emitted photons and the amount of FITC by measuring the FITC volume using AFM. Finally, we estimated the quantity of Aβ peptides of the cells placed on the p-FET sensing area on the basis of the binding ratio between FITC molecules and Aβ peptides.
This research was supported by the Converging Research Center Program funded by the Ministry of Education, Science and Technology (2011K000677)of Korea.
- Bertram L, Tanzi RE: Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9: 768–778. 10.1038/nrn2494View ArticleGoogle Scholar
- Williamson J, Goldman J, Marder K: Genetic aspects of Alzheimer disease. Neurologist 2009, 15: 80–86. 10.1097/NRL.0b013e318187e76bView ArticleGoogle Scholar
- Small DH, Mok SS, Bornstein JC: Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci 2001, 2: 595–598. 10.1038/35086072View ArticleGoogle Scholar
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997, 94: 13287–13292. 10.1073/pnas.94.24.13287View ArticleGoogle Scholar
- Nussbaum RL, Ellis CE: Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348: 1356–1364. 10.1056/NEJM2003ra020003View ArticleGoogle Scholar
- Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, Kneuer R, Neumann U, Rudin M, Staufenbiel M, Stoeckli M, Wiederhold KH, Gremlich HU: In vivo detection of amyloid-b deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005, 23: 577–583. 10.1038/nbt1085View ArticleGoogle Scholar
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Sci 2002, 297: 353–356. 10.1126/science.1072994View ArticleGoogle Scholar
- Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, Staufenbiel M, Jucker M: Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003, 6: 370–377. 10.1038/nn1022View ArticleGoogle Scholar
- Small DH, McLean CA: Alzheimer's disease and the amyloid b protein: what is the role of amyloid? J Neurochem 1999, 73: 443–449.View ArticleGoogle Scholar
- Sisodia SS, Price DL: Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 1995, 9: 366–370.Google Scholar
- Lin H, Bhatia R, Lal R: Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 2001, 15: 2433–2444. 10.1096/fj.01-0377comView ArticleGoogle Scholar
- Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007, 8: 101–112. 10.1038/nrm2101View ArticleGoogle Scholar
- Bonte FJ, Harris TS, Hynan LS, Bigio EH, White CL: Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation. Clin Nucl Med 2006, 31: 376–378. 10.1097/01.rlu.0000222736.81365.63View ArticleGoogle Scholar
- Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR: In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurol 1999, 52: 691–699.View ArticleGoogle Scholar
- Barbee KD, Hsiao AP, Roller EE, Huang X: Multiplexed protein detection using antibody-conjugated microbead arrays in a microfabricated electrophoretic device. Lab Chip 2010, 10: 3084–3093. 10.1039/c0lc00044bView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.